Last reviewed · How we verify
baricitinib treatment
Baricitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which play a role in inflammation.
Baricitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which play a role in inflammation. Used for Rheumatoid arthritis, Psoriatic arthritis.
At a glance
| Generic name | baricitinib treatment |
|---|---|
| Sponsor | University Hospital, Bordeaux |
| Drug class | JAK inhibitor |
| Target | JAK |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting JAK enzymes, baricitinib reduces the production of pro-inflammatory cytokines, leading to decreased inflammation. This mechanism is particularly useful in treating autoimmune diseases such as rheumatoid arthritis.
Approved indications
- Rheumatoid arthritis
- Psoriatic arthritis
Common side effects
- Increased risk of infections
- Increased risk of thrombocytopenia
- Increased risk of liver enzyme elevations
Key clinical trials
- Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis (PHASE1)
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (PHASE3)
- Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis
- Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) (PHASE2)
- Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study (PHASE2)
- Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis (PHASE3)
- Efficacy and Safety of Baricitinib in Sjogren's Syndrome (PHASE2)
- Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- baricitinib treatment CI brief — competitive landscape report
- baricitinib treatment updates RSS · CI watch RSS
- University Hospital, Bordeaux portfolio CI